Solara Active Pharma Q1'27: Revenue Up 20% to ₹3,843 Mn, Highest EBITDA & PAT in 18 Quarters
Solara Active Pharma reported Q1'27 results with overall revenues up 20% YoY to ₹3,843 Mn. EBITDA rose 10% to ₹635 Mn and PAT increased 55% to ₹163 Mn, the highest in 18 quarters. Base business revenues grew 24% YoY to ₹3,077 Mn. Net debt reduced by ₹1,346 Mn to ₹4,795 Mn.
The strong financial performance, record profitability, and significant debt reduction are material positive developments for the company and its stakeholders.
The company reported strong year-on-year growth in revenues, EBITDA, and PAT, reaching an 18-quarter high. Significant debt reduction also contributes positively.
Solara Active Pharma Sciences Limited has reported its financial results for the quarter ended June 30, 2026 (Q1'27), showcasing strong year-on-year growth and improved profitability. The company's overall revenues increased by 20% to ₹3,843 million (Mn), with EBITDA rising by 10% to ₹635 Mn and Profit After Tax (PAT) growing by 55% to ₹163 Mn. This marks the highest EBITDA and PAT reported in the last eighteen quarters.
The Base business (excluding Ibuprofen) demonstrated robust performance, with revenues up 24% year-on-year to ₹3,077 Mn and EBITDA up 8% to ₹722 Mn. Despite higher input costs due to geopolitical developments in West Asia, the Base business maintained strong gross margins of approximately 51% and EBITDA margins of around 24%. Regulated markets continue to contribute over 75% of revenues.
The Ibuprofen business, however, reported revenues of ₹765 Mn with an EBITDA loss of ₹87 Mn, reflecting ongoing profitability challenges. The company is evaluating strategic options for this business, with a decision expected by the end of Q2'27. The carve-out of polymers and CRAMS businesses remains on hold until the Ibuprofen business strategy is finalized.
Solara also reported a significant reduction in net debt, which decreased by ₹1,346 Mn during the quarter to ₹4,795 Mn. This brings the net debt to EBITDA ratio to approximately 1.9 times on an annualized basis. The company anticipates a further reduction in net debt to around ₹4,406 Mn by March 2027.
An earnings conference call is scheduled for Friday, July 23, 2026, at 16:00 hrs IST, with CFO Sarat Kumar and MD & CEO Sandeep Rao participating.
What to do with a filing like this
Solara Active Pharma Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Solara Active Pharma Sciences Limited. Read the original for the full detail.